# China Allergy Immunotherapy Market > China Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) andBy Patient Type (Pediatric, Adult, Geriatric)- Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.43% - **2018:** $ 319.2 Million - **2024:** $ 169.8 Million - **2035:** $ 457.62 Million - **Key Players:** Boehringer Ingelheim (DE), Allergopharma (DE), Merck KGaA (DE), Stallergenes Greer (GB), Aimmune Therapeutics (US), DBV Technologies (FR), Novartis (CH), Sanofi (FR), Bristol-Myers Squibb (US) **Report ID:** MRFR/HC/54532-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-allergy-immunotherapy-market-56298 --- ## Market Summary **China Allergy Immunotherapy Market Overview****:** **As per MRFR analysis, the China Allergy Immunotherapy Market Size was estimated at 319.2 (USD Million) in 2023. The China Allergy Immunotherapy Market Industry is expected to grow from 342.6(USD Million) in 2024 to 750 (USD Million) by 2035. The China Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 7.383% during the forecast period (2025 - 2035).** **Key China Allergy Immunotherapy Market Trends Highlighted** A variety of factors in the China Allergy Immunotherapy Market is driving notable trends. The population's growing awareness of allergic diseases is one of the primary market drivers. An increased demand for effective treatment options has resulted from the increase in allergies caused by urbanization, pollution, and lifestyle changes. In addition, the Chinese government is promoting advanced treatments, including immunotherapy, and is also prioritizing research and development in allergology. This generates an advantageous atmosphere for market expansion. In addition, the implementation of favorable healthcare policies and regulations is creating new opportunities for both domestic and foreign companies to establish a presence in the market. An increasing number of patients are seeking affordable and accessible allergy treatments, such as immunotherapy, as health insurance coverage expands. There has been a recent increase in the movement toward personalized medicine in the treatment of allergies. China's healthcare providers are increasingly emphasizing the importance of customizing immunotherapy regimens to the unique profiles of individual patients, resulting in more effective outcomes. In addition, the integration of digital health tools and technologies is gaining momentum, as telemedicine and remote patient monitoring are becoming essential for the management of allergies and the enforcement of treatment plans. With the increasing prevalence of allergic conditions and the aging of the Chinese population, there is a growing need for innovative allergy management solutions.Overall, the allergy immunotherapy sector in China offers substantial opportunities for stakeholders who are prepared to capitalize on the advancements in medical technology and adapt to evolving consumer demands. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **China Allergy Immunotherapy Market Drivers** Increasing Prevalence of Allergies in China The rise in the prevalence of allergic conditions, such as allergic rhinitis, asthma, and eczema, is one of the main drivers for the growth of the China Allergy Immunotherapy Market Industry. Data from the Chinese Center for Disease Control and Prevention reported that the incidence of allergic diseases has increased by approximately 28% between 2015 and 2020, affecting over 400 million individuals in the country. This significant rise in allergy cases propels the demand for effective treatment options, particularly immunotherapy, which is recognized for its potential to provide long-lasting relief.Moreover, organizations like the China Allergy Society are actively working to raise awareness and promote better management of allergic diseases, thereby enhancing the need for immunotherapy solutions. Government Initiatives and Support for Allergy Treatment The Chinese government has taken pivotal steps to bolster the treatment of allergic conditions through regulatory frameworks and policy support aimed at improving accessibility to immunotherapy. The National Health Commission of China has emphasized the importance of addressing allergy-related healthcare needs in its recent healthcare reforms, focusing on providing comprehensive allergy management services. These initiatives are projected to facilitate public awareness and encourage investment in the Allergy Immunotherapy sector.With funding and support from government organizations, the China Allergy Immunotherapy Market Industry is expected to gain momentum, enabling more patients to access timely treatment and improving overall health outcomes. Advancements in Allergy Immunotherapy Techniques Recent advancements in allergy immunotherapy techniques, including sublingual and injectable immunotherapies, are significantly contributing to the growth of the Allergy Immunotherapy Market Industry in China. Research and Development efforts by established pharmaceutical companies, such as Dong-A ST and LEO Pharma, have led to the introduction of innovative treatments that are gaining acceptance among healthcare providers and patients alike. According to the China Food and Drug Administration, there has been an increasing number of approvals for allergy immunotherapy products, showing a 50% increase in approvals from 2018 to 2022.This advancement aligns with China's ongoing efforts to enhance healthcare standards and ultimately expand treatment options in the market. Growing Awareness and Acceptance of Immunotherapy The increasing awareness and acceptance of allergy immunotherapy among healthcare professionals and patients is driving the market growth substantially. Educational programs and outreach initiatives by leading healthcare organizations in China are aimed at better educating the populace about the benefits of immunotherapy over traditional allergy treatments. A survey conducted by the Chinese Society of Allergology indicated that knowledge of immunotherapy as a treatment option has improved by approximately 60% amongst healthcare providers in urban areas in the last five years.With this shift in understanding, more patients are being referred for immunotherapy treatments, contributing to the upward trajectory of the China Allergy Immunotherapy Market Industry. **China Allergy Immunotherapy Market Segment Insights****:** **Allergy Immunotherapy Market Type Insights** The China Allergy Immunotherapy Market is characterized by a diverse range of treatment options categorized under the Type segment, which includes Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. The increasing prevalence of allergies in China, driven by urbanization, environmental changes, and lifestyle modifications, has heightened the demand for effective allergy treatment methods, leading to significant developments in this market space. Among these treatment modalities, Subcutaneous Immunotherapy has emerged as a dominant approach, mainly due to its efficacy in treating allergic rhinitis and asthma, offering long-term relief for patients. This method typically involves administering allergenic extracts through injections, and its well-established protocol in clinical settings has contributed to its widespread adoption.Sublingual Immunotherapy is gaining traction due to its non-invasive nature and the convenience it offers patients, making treatment more comfortable and accessible. By allowing patients to self-administer doses under the tongue, this method eliminates the need for frequent clinic visits. It reduces the burden on healthcare systems, particularly in densely populated areas. As a result, it's fast becoming a preferred choice, particularly among those who may be apprehensive about needles. Furthermore, Oral Immunotherapy is an emerging trend in the market, catering to specific allergies with oral consumption of allergenic food proteins. This approach is particularly important in addressing food allergies, which are on the rise in China. The shift toward such innovative treatments aligns with evolving patient preferences and a desire for more tailored therapeutic options.Government initiatives in China also play a pivotal role in the growth and acceptance of these immunotherapy types, with a focus on increasing awareness and training for healthcare professionals. The ongoing research efforts to enhance the safety and effectiveness of these therapies continue to propel market growth, as does the rising awareness of the benefits of long-term treatment strategies for allergy management. The combination of increased patient engagement in treatment choices and advancements in Immunotherapy technology contributes to the expanding landscape of the China Allergy Immunotherapy Market, allowing for improved patient outcomes and quality of life. Each treatment type continues to hold immense potential in transforming allergy care, underscoring the market's dynamic nature and its capabilities to address the varying needs of patients battling allergies in China. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Allergy Immunotherapy Market Product Insights** The China Allergy Immunotherapy Market is shaped significantly by its Product segment, which can be categorized into Allergen Extracts, Conventional Immunotherapy, and Biologics. Allergen Extracts play a crucial role as they are vital in desensitizing patients to specific allergens, thus addressing the rising incidence of allergies in China due to environmental factors and urbanization. Conventional Immunotherapy remains a staple in allergy treatment, providing long-term relief for patients and enjoying widespread acceptance among healthcare providers.Biologics have emerged as a promising frontier, often offering targeted therapies that can be more effective and tailored for specific patient populations, contributing to the overall diversification within the market. The increasing prevalence of allergic conditions among the Chinese population drives demand across all these areas, further adding to the complexity and opportunities in the market. Additionally, the regulatory landscape in China supports research and development in immunotherapy, fueling advancements that can enhance the efficacy and safety of treatment options available to patients.Overall, each segment holds its unique significance and collectively contributes to the evolving landscape of the China Allergy Immunotherapy Market. **Allergy Immunotherapy Market Indication Insights** The China Allergy Immunotherapy Market is increasingly being shaped by the growing prevalence of allergic conditions within the population, emphasizing the significance of indications like Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Allergic Rhinitis holds a prominent share due to urban air pollution and pollen exposure. At the same time, Allergic Asthma is impacted by environmental triggers prevalent in urbanized areas, making it a critical focus for treatment advancements. Atopic Dermatitis is gaining attention with rising awareness about skin sensitivities and the need for effective management solutions in children and adults.Food Allergies are becoming a major concern as dietary habits evolve and awareness increases, necessitating innovative therapeutic options. With the rising incidence of these allergic conditions in China, there is a heightened demand for effective immunotherapy solutions tailored to specific indications, driving research initiatives toward developing new therapies aimed at alleviating symptoms and improving the quality of life for affected individuals. The heightened focus on these indications highlights the dynamic nature of the toxicity landscape and potential growth opportunities in the China Allergy Immunotherapy Market. **Allergy Immunotherapy Market Patient Type Insights** The China Allergy Immunotherapy Market is characterized by its diverse Patient Type segmentation, encompassing Pediatric, Adult, and Geriatric populations. Each group presents unique challenges and opportunities in the realm of allergy treatment. The Pediatric segment is particularly pivotal, as early interventions can significantly alter lifetime health outcomes for children suffering from allergies, making effective immunotherapy a critical focus for practitioners. The Adult segment often dominates the market due to a higher prevalence of allergic conditions in this demographic, spurred by urbanization and lifestyle changes, which increase exposure to allergens.Furthermore, Geriatric patients are becoming increasingly significant as the aging population in China grows, highlighting the need for tailored immunotherapy approaches that address the complexities of treating allergies in elderly individuals. The increasingly diverse range of allergens and personalized treatment strategies in these segments reflect the dynamics of the China Allergy Immunotherapy Market, underlining the necessity for ongoing research and development to cater to the distinct needs of each patient group. Overall, this segmentation strategy enhances treatment efficacy and aligns with China’s commitment to improving healthcare outcomes. **China Allergy Immunotherapy Market Key Players and Competitive Insights****:** The competitive insights of the China Allergy Immunotherapy Market reveal a diverse landscape marked by a blend of established players, innovative newcomers, and a growing emphasis on patient-centered approaches. This sector is heavily influenced by the rising prevalence of allergies in the region, which has stimulated demand for effective immunotherapy options. Manufacturers are focusing on developing advanced allergen immunotherapies, enhancing delivery methods, and achieving regulatory compliance to strengthen their market position. The competitive dynamics underscore the importance of product differentiation, strategic partnerships, and marketing capabilities as companies vie for a larger share in this burgeoning sector. With increasing awareness of allergy treatments and supportive government policies, the market presents significant opportunities for both existing and emerging players.In this competitive landscape, Happymeds stands out with its commitment to patient education and innovative treatment solutions tailored to the Chinese market. Focused on delivering high-quality allergy immunotherapy products, Happymeds has successfully cultivated a strong brand presence among healthcare professionals and patients alike. The company's strengths lie in its rigorous research and development efforts, leading to the launch of new and effective treatments that resonate with the needs of the Chinese population. Additionally, Happymeds has forged strategic alliances with key healthcare providers, enhancing its distribution channels and expanding its market reach. This proactive approach has allowed the company to strengthen its position within the allergy immunotherapy market, ensuring that it remains a trusted name in the industry.Sinopharm Group is another prominent player in the China Allergy Immunotherapy Market, recognized for its extensive portfolio of products and services. The company has made significant strides in developing and distributing a range of allergy treatments that cater to diverse patient needs, including standardized immunotherapy and allergenic extracts. With a well-established distribution network across China, Sinopharm Group has effectively leveraged its nationwide presence to enhance access to its products, ensuring that patients receive timely and effective care. The company’s strengths also include strong collaborations with research institutions and frequent involvement in mergers and acquisitions, which bolster its research capabilities and expand its market offerings. Such strategic initiatives have positioned Sinopharm Group as a leader in the allergy immunotherapy sector within China, illustrating its commitment to advancing treatment options and improving patient outcomes in the field of allergy management. **Key Companies in the China Allergy Immunotherapy Market Include:** Happymeds Sinopharm Group Jiangsu Hengrui Medicine Hua Medicine BeiGene Sino Biopharmaceutical Wuhan Fuxing Science and Technology Guangzhou Baiyunshan Pharmaceutical Holdings Huangming Pharmaceutical Shenzhen Salubris Pharmaceuticals **China Allergy Immunotherapy Market Industry Developments** _The China Allergy Immunotherapy Market has seen significant developments recently, characterized by advancements in both technology and regulatory approvals. Notable companies such as Jiangsu Hengrui Medicine and Sinopharm Group are intensifying their Research and Development efforts in personalized allergy treatments, aiming to enhance efficacy and patient compliance. In July 2023, BeiGene announced a collaboration with Hua Medicine to develop innovative immunotherapies that target specific allergens, reflecting the growing trend of partnerships to accelerate product pipelines in this sector.____Moreover, the market is witnessing increased investments, with Wuhan Fuxing Science and Technology reporting a substantial growth in valuation due to an influx of funding for their allergen immunotherapy devices. Merger and acquisition activities have also been prominent; in August 2023, Shenzhen Salubris Pharmaceuticals completed the acquisition of Guangzhou Baiyunshan Pharmaceutical Holdings, which is expected to strengthen__its__portfolio in the allergy treatment domain. This consolidation is indicative of a broader trend aimed at enhancing market presence and expanding therapeutic offerings. Over the past two years, innovation in formulations and an emphasis on regulatory compliance have further driven competitiveness among market players, paving the way for growth in China's allergy immunotherapy landscape._ **China Allergy Immunotherapy Market Segmentation Insights** **Allergy Immunotherapy Market Type****Outlook** **Subcutaneous Immunotherapy** **Sublingual Immunotherapy** **Oral Immunotherapy** **Allergy Immunotherapy Market Product****Outlook** **Allergen Extracts** **Conventional Immunotherapy** **Biologics** **Allergy Immunotherapy Market Indication****Outlook** **Allergic Rhinitis** **Allergic Asthma** **Atopic Dermatitis** **Food Allergies** **Allergy Immunotherapy Market Patient Type****Outlook** **Pediatric** **Adult** **Geriatric** **** ## Market Drivers ### Supportive Regulatory Environment The supportive regulatory environment in China plays a crucial role in fostering the growth of the China [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market. The government has implemented policies aimed at promoting the development and approval of new immunotherapy products. In 2025, the National Medical Products Administration streamlined the approval process for allergy treatments, reducing the time required for new therapies to reach the market. This regulatory support encourages pharmaceutical companies to invest in research and development, leading to a wider array of treatment options for patients. As the regulatory landscape continues to evolve favorably, it is anticipated that the market will experience accelerated growth. ### Rising Awareness of Allergy Treatments The growing awareness regarding allergy treatments among the Chinese population is a notable driver for the China Allergy Immunotherapy Market. As more individuals become informed about the benefits of immunotherapy, there is an increasing demand for these treatments. Public health campaigns and educational initiatives have contributed to this awareness, leading to a rise in patient inquiries and consultations. In 2025, it was estimated that approximately 30 million people in China were seeking allergy treatments, indicating a substantial market potential. This heightened awareness is likely to propel the growth of the immunotherapy sector, as patients actively seek effective solutions for their allergy-related issues. ### Rising Incidence of Allergic Conditions The increasing incidence of allergic conditions in China is a critical driver for the China Allergy Immunotherapy Market. Reports indicate that the prevalence of allergic rhinitis and asthma has been on the rise, affecting millions of individuals across the country. In 2025, it was estimated that around 20% of the Chinese population suffered from some form of allergy, creating a substantial demand for effective treatment options. This trend is likely to continue, as urbanization and environmental factors contribute to the worsening of allergic conditions. Consequently, the growing patient population seeking immunotherapy is expected to drive the market forward. ### Advancements in Immunotherapy Techniques Technological advancements in immunotherapy techniques are significantly influencing the China Allergy Immunotherapy Market. Innovations such as sublingual immunotherapy and monoclonal antibodies have emerged, providing patients with more effective and convenient treatment options. In 2025, the introduction of new immunotherapy products led to a 15% increase in market growth compared to the previous year. These advancements not only enhance treatment efficacy but also improve patient compliance, as newer methods often involve less frequent dosing. As research and development continue to progress, the market is likely to witness further innovations that will attract more patients to seek immunotherapy. ### Increased Investment in Healthcare Infrastructure The Chinese government has been investing heavily in healthcare infrastructure, which is a significant driver for the China Allergy Immunotherapy Market. Enhanced healthcare facilities and the establishment of specialized allergy clinics have made immunotherapy more accessible to patients. In 2025, the healthcare expenditure in China reached over 6 trillion yuan, with a portion allocated specifically for allergy treatments. This investment not only improves the quality of care but also encourages the development of new immunotherapy products. As healthcare infrastructure continues to expand, it is expected that more patients will have access to allergy immunotherapy, thereby stimulating market growth. ## Future Outlook The China Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising healthcare expenditure. **New opportunities:** - Development of personalized immunotherapy solutions for specific allergens. Expansion of telehealth platforms for remote allergy consultations. Investment in AI-driven diagnostics for allergy identification and treatment optimization. By 2035, the market is expected to be robust, reflecting substantial growth and innovation. ## Segment Insights ### By Application: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing) In the China Allergy Immunotherapy Market, the application segments exhibit distinct characteristics in terms of market share. Allergic Rhinitis leads as the largest segment, driven by its high prevalence among the population. In contrast, Allergic Asthma and [Atopic Dermatitis](https://www.marketresearchfuture.com/reports/atopic-dermatitis-market-1610) are also significant but take a relatively smaller share, while Food Allergies continue to maintain a stable presence, potentially showing gradual growth in awareness and diagnosis. The distribution reflects the varying degrees of awareness and treatment options available for these conditions in the region. Growth trends within this segment indicate a promising trajectory for Allergic Asthma, which is recognized as the fastest-growing segment due to increasing pollution levels and lifestyle changes triggering respiratory issues. There is also a growing focus on personalized immunotherapy treatments, alongside robust awareness campaigns that are helping to drive the increase in market participation for these conditions. Such trends highlight the adaptive nature of the immunotherapy market in response to changing health needs and consumer awareness. Allergic Rhinitis (Dominant) vs. Atopic Dermatitis (Emerging) The characteristics of Allergic Rhinitis position it as the dominant segment within the China Allergy Immunotherapy Market, attributed to its widespread occurrence among individuals, especially in urban areas with higher pollution levels. Treatment approaches for Allergic Rhinitis have become conventional and include various immunotherapy options, making it a staple in allergy management. Meanwhile, Atopic Dermatitis is emerging as a segment gaining traction, characterized by increased research and development investments, targeting consumer education, and the introduction of novel treatment options. With rising cases of skin allergies, Atopic Dermatitis is witnessing enhanced focus from both healthcare providers and pharmaceutical companies, indicating a shift towards broader immunotherapy applications in the future. ### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing) The China Allergy Immunotherapy Market displays a diverse array of treatment options, with Subcutaneous Immunotherapy leading the market as the largest segment. This method, which involves the administration of allergen extracts through injections, has garnered significant acceptance due to its long history and proven efficacy. Following closely is Sublingual Immunotherapy, which has been rapidly gaining traction among patients seeking a more convenient and less invasive alternative. Its ease of administration contributes to a growing population of patients opting for this method. In recent years, there has been a notable shift towards Sublingual Immunotherapy as it offers a favorable safety profile and the convenience of self-administration, driving its growth in the market. Increased awareness about allergic disorders and the efficacy of immunotherapy has led to more individuals seeking treatment. Furthermore, supportive regulatory frameworks and advancements in formulation techniques are expected to foster the growth of both Subcutaneous and Sublingual approaches, shaping the future landscape of allergy treatment in China. Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging) Subcutaneous Immunotherapy remains the dominant player in the China Allergy Immunotherapy Market due to its established effectiveness and comprehensive clinical validation over the years. Patients typically receive a series of injections that gradually increase the dosage of allergens, which helps build immunity over time. This method is particularly suited for individuals with severe allergies and provides long-lasting results. However, the rising popularity of Sublingual Immunotherapy as an emerging option signals a shift in patient preference, particularly among those looking for less invasive treatment alternatives. Sublingual therapy, which allows patients to place allergen tablets or drops under their tongue, is perceived as more user-friendly and is leading to increased patient adherence. As healthcare providers continue to recognize its benefits, Sublingual Immunotherapy is likely to expand its foothold in the market. ### By Patient Demographics: Children (Largest) vs. Adults (Fastest-Growing) In the China Allergy Immunotherapy Market, patient demographics play a crucial role in market dynamics. Children represent the largest segment, largely driven by the increasing prevalence of allergic conditions among this age group. As awareness about allergy management grows among parents, there has been a significant rise in immunotherapy adoption for pediatric patients, leading them to command a substantial share of the market. Meanwhile, adults emerge as the fastest-growing segment, attributed to lifestyle changes, environmental factors, and rising incidences of adult-onset allergies, which have elevated the demand for effective treatment options in this demographic. The growth trends in this segment reflect broader societal changes, including increased urbanization and pollution levels in China, prompting more adults to seek relief from allergy symptoms through immunotherapy. Recent studies indicate improvements in awareness and acceptance of allergy treatments, further fueling this growth. Moreover, the expansion of access to healthcare and evolving treatment protocols are catering to the needs of both segments, thereby enhancing overall market progression. This trend is expected to continue as more targeted therapies and patient education initiatives unfold over the coming years. Children: Dominant vs. Adults: Emerging The segment of children remains dominant in the China Allergy Immunotherapy Market, primarily due to their heightened vulnerability to allergies, which have markedly increased in prevalence over recent years. Children, particularly those exposed to environmental allergens, are often the prime targets for early intervention through immunotherapy, as parents seek proactive treatments to alleviate severe allergic reactions. On the other hand, the adult segment is emerging strongly, driven by lifestyle changes and an increase in awareness of adult allergies. Adults increasingly recognize the impact of allergies on their quality of life, prompting a shift towards innovative immunotherapy solutions. The distinct characteristics of both demographics highlight a dual focus for providers, emphasizing preventive measures for children and tailored approaches for adults to meet their unique treatment needs. ### By Treatment Duration: Long-term (Largest) vs. Maintenance Therapy (Fastest-Growing) In the China Allergy Immunotherapy Market, the treatment duration segment is characterized by a diverse array of options, prominently featuring Long-term therapy, which captures the largest market share. Short-term and Induction therapy segments also contribute significantly, but their market positions are comparatively lower. Maintenance Therapy is gaining traction as patients seek ongoing relief, establishing itself as a notable contender within this segment. Growth trends within the treatment duration segment are influenced by increasing awareness of allergy immunotherapy benefits and the need for sustained treatment options. As healthcare providers emphasize the importance of long-term management of allergic conditions, Long-term therapy remains dominant. However, Maintenance Therapy is emerging as the fastest-growing segment, driven by patient adherence and the convenience of continuous care as a preferred option for managing allergies. Long-term (Dominant) vs. Maintenance Therapy (Emerging) Long-term therapy represents the dominant approach within the China Allergy Immunotherapy Market, characterized by its ability to provide sustained relief from allergy symptoms through prolonged treatment. This method is often favored for its effectiveness in achieving lasting desensitization. In contrast, Maintenance Therapy has emerged as a vital alternative, appealing to patients seeking ongoing care with minimal disruption to their daily lives. It allows for personalized treatment plans that ensure continuous management of allergic reactions. This shift towards Maintenance Therapy indicates a growing trend where patients prefer sustained approaches accompanied by regular check-ups and adjustments based on their individual responses, reflecting a broader demand for flexible and patient-centered care strategies. ## Competitive Benchmarking The China Allergy Immunotherapy Market is currently characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as Boehringer Ingelheim (DE), Merck KGaA (DE), and Aimmune Therapeutics (US) are strategically positioning themselves through innovation and regional expansion. Boehringer Ingelheim (DE) has focused on enhancing its product portfolio with novel therapies, while Merck KGaA (DE) emphasizes partnerships to bolster its research capabilities. Aimmune Therapeutics (US) is actively pursuing collaborations to expedite the development of its peanut allergy treatment, thereby shaping a competitive environment that prioritizes innovation and strategic alliances. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. This fragmentation is influenced by the diverse needs of patients and healthcare providers, which necessitates tailored solutions. The collective influence of key players is significant, as they drive advancements in treatment options and patient access, thereby enhancing the overall market structure. In January 2026, Aimmune Therapeutics (US) announced a strategic partnership with a leading Chinese pharmaceutical company to enhance the distribution of its peanut allergy immunotherapy. This collaboration is expected to facilitate faster market entry and improve accessibility for patients in China, reflecting Aimmune's commitment to addressing local needs. The strategic importance of this partnership lies in its potential to significantly increase Aimmune's market presence and drive revenue growth in a rapidly evolving landscape. In December 2025, Merck KGaA (DE) launched a new digital platform aimed at educating healthcare professionals about the benefits of immunotherapy. This initiative underscores the company's focus on digital transformation and its recognition of the need for enhanced education in the market. By leveraging technology, Merck KGaA (DE) aims to improve treatment adoption rates and foster stronger relationships with healthcare providers, which could lead to increased market penetration. In November 2025, Boehringer Ingelheim (DE) expanded its research and development facilities in China, signaling a long-term commitment to the region. This expansion is likely to enhance the company's ability to innovate and respond to local market demands. The strategic importance of this move lies in its potential to accelerate the development of new therapies tailored to the unique needs of Chinese patients, thereby strengthening Boehringer's competitive position. As of February 2026, current trends in the China Allergy Immunotherapy Market indicate a shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on technology and supply chain reliability rather than solely on price. This shift suggests that companies that prioritize innovation and adaptability will likely emerge as leaders in the market. ## Recent News & Developments _The China Allergy Immunotherapy Market has seen significant developments recently, characterized by advancements in both technology and regulatory approvals. Notable companies such as Jiangsu Hengrui Medicine and Sinopharm Group are intensifying their Research and Development efforts in personalized allergy treatments, aiming to enhance efficacy and patient compliance. In July 2023, BeiGene announced a collaboration with Hua Medicine to develop innovative immunotherapies that target specific allergens, reflecting the growing trend of partnerships to accelerate product pipelines in this sector.__Moreover, the market is witnessing increased investments, with Wuhan Fuxing Science and Technology reporting a substantial growth in valuation due to an influx of funding for their allergen immunotherapy devices. Merger and acquisition activities have also been prominent; in August 2023, Shenzhen Salubris Pharmaceuticals completed the acquisition of Guangzhou Baiyunshan Pharmaceutical Holdings, which is expected to strengthen__its__portfolio in the allergy treatment domain. This consolidation is indicative of a broader trend aimed at enhancing market presence and expanding therapeutic offerings. Over the past two years, innovation in formulations and an emphasis on regulatory compliance have further driven competitiveness among market players, paving the way for growth in China's allergy immunotherapy landscape._ ## Report Scope Report Scope: | Report Attribute/Metric Source: | Details | | --- | --- | | MARKET SIZE 2018 | 319.2(USD Million) | | MARKET SIZE 2024 | 342.6(USD Million) | | MARKET SIZE 2035 | 750.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.383% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | MARKET FORECAST PERIOD | 2025 - 2035 | | HISTORICAL DATA | 2019 - 2024 | | MARKET FORECAST UNITS | USD Million | | KEY COMPANIES PROFILED | Happymeds, Sinopharm Group, Jiangsu Hengrui Medicine, Hua Medicine, BeiGene, Sino Biopharmaceutical, Wuhan Fuxing Science and Technology, Guangzhou Baiyunshan Pharmaceutical Holdings, Huangming Pharmaceutical, Shenzhen Salubris Pharmaceuticals | | SEGMENTS COVERED | Type, Product, Indication, Patient Type | | KEY MARKET OPPORTUNITIES | Increasing prevalence of allergies, Growing investment in R&D, Expanding patient awareness programs, Advancements in personalized therapies, Rising demand for effective treatments | | KEY MARKET DYNAMICS | increasing allergy prevalence, government support for research, growing patient awareness, advancements in treatment options, competitive market landscape | | COUNTRIES COVERED | China | ## Frequently Asked Questions **Q: What is the current valuation of the China Allergy Immunotherapy Market?** A: The market valuation was 169.8 USD Million in 2024. **Q: What is the projected market size for the China Allergy Immunotherapy Market by 2035?** A: The projected valuation for 2035 is 457.62 USD Million. **Q: What is the expected CAGR for the China Allergy Immunotherapy Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 9.43%. **Q: Which segments are included in the China Allergy Immunotherapy Market?** A: The market segments include Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. **Q: What are the key types of immunotherapy in the market?** A: Key types of immunotherapy include Subcutaneous, Sublingual, Oral, and Intranasal Immunotherapy. **Q: How does the market perform across different patient demographics?** A: The market performance varies, with Adults projected to generate 70.0 to 200.0 USD Million. **Q: What is the revenue range for Allergic Rhinitis in the market?** A: The revenue range for Allergic Rhinitis is between 50.0 and 130.0 USD Million. **Q: Which companies are leading the China Allergy Immunotherapy Market?** A: Key players include Boehringer Ingelheim, Merck KGaA, and Novartis. **Q: What is the revenue range for Sublingual Immunotherapy?** A: Sublingual Immunotherapy is projected to generate between 40.0 and 120.0 USD Million. **Q: What are the expected revenue ranges for long-term treatment in the market?** A: Long-term treatment is expected to generate between 51.84 and 138.12 USD Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-allergy-immunotherapy-market-56298*